Pulmonary Hypertension, Quality of Life and Psychosocial Factors (HyPsy)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01380054|
Recruitment Status : Completed
First Posted : June 27, 2011
Last Update Posted : January 5, 2018
The investigators aim to :
- describe and analyse psychological characteristics, cognitive factors and representations in patients with Pulmonary Hypertension, a rare disease.
- assess the psychological characteristics impact on quality of life, check the association between disease and QoL evolution, and the variability of QoL parameters over severity class changes and follow-up
|Condition or disease||Intervention/treatment|
|Pulmonary Hypertension||Behavioral: Evaluation of quality of life|
PAH is a rare, and severe disease, potentially mortal, affecting preferentially young subjects. The knowledge and the international literature, as regards the quality of life, the expectations, the needs and the psychosocial characteristics of patients with PAH, are non-existent. But it is known that the persons affected by rare diseases are more vulnerable, on the psychological, social, economic and cultural planIn all the stages of the treatment, patients with PAH are confronted with heavy psychosocial situations, in a context of vital risk, with exceptional medicinal treatments (intravenous administration at home).
- QoL might be differently affected by these changes according to situational and dispositional psychological dimensions.
- the predictive role of these characteristics on the current and later quality of life, as well as the impact of diverse cognitive mediators and strategies to cope with the disease, should be investigated.The respiratory diseases department of the Montpellier hospital is regional competence center for PAH in Languedoc-Roussillon, under the aegis of the national reference center (the respiratory diseases department of Antoine Béclère hospital, Le Petit-Clamart).
|Study Type :||Observational|
|Actual Enrollment :||55 participants|
|Official Title:||Pulmonary Hypertension: Impact of the Evolution of a Rare Disease on the Quality of Life and Role of Variables Psychosocial as Predictive of the Current and Later Quality of Life|
|Actual Study Start Date :||May 31, 2011|
|Actual Primary Completion Date :||May 20, 2016|
|Actual Study Completion Date :||May 20, 2016|
|patients with pulmonary hypertension||
Behavioral: Evaluation of quality of life
-Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36
- Descriptive analysis of psychological characteristics on PAH patients [ Time Frame: 36 months ]The descriptive analysis of psychological characteristics (anxiety, depression, social support, coping, control beliefs) is evaluated at entry and at one year. These psychological characteristics are evaluated by score of psychological questionnaires.
- Psychological characteristics impact on Quality of life [ Time Frame: 36 months ]The quality of life is measured by the score of the SF 36, the stage of the disease is codified by the NYHA, Qualitative and quantitative analysis of contents of the audio bands by the psychologist implicated to this study.
- Association between disease and Quality of life evolution [ Time Frame: 36 months ]The quality of life is measured by the score of the SF 36, the stage of the disease is codified by the NYHA, Qualitative and quantitative analysis of contents of the audio bands by the psychologist implicated to this study.
- Variability of Quality of life parameters over severity class changes and follow-up [ Time Frame: 36 months ]The quality of life is measured by the score of the SF 36, the stage of the disease is codified by the NYHA, Qualitative and quantitative analysis of contents of the audio bands by the psychologist implicated to this study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01380054
|Montpellier, France, 34295|
|Study Director:||Bourdin Arnaud, MD, PhD||University Hospital, Montpellier|